Canada markets closed

HAVN Life Sciences Inc. (HAVLF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.1786-0.0058 (-3.16%)
At close: 03:50PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close0.1844
Open0.1837
BidN/A x N/A
AskN/A x N/A
Day's Range0.1760 - 0.1990
52 Week Range0.1510 - 0.9800
Volume64,184
Avg. Volume86,348
Market Cap22.124M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • CNW Group

    HAVN Life to Present at upcoming SNN Network Canada Virtual Event

    Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the "Company" or "Havn Life") a biotechnology company pursuing standardized extraction of psychedelic compounds for the creation of APIs that support brain health and enhance the capabilities of the mind, is announcing that CEO Tim Moore will be presenting at the SNN Network Canada Virtual Event 2021 on Wednesday, December 8 at 2:30pm EST. Mr. Moore will also host a Q & A session for investors following his presentation.

  • CNW Group

    HAVN Life Successfully Exports Psilocybin from its Jamaica Facility into Canada

    Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the "Company" or "Havn Life") a biotechnology company pursuing standardized extraction of psychedelic compounds for the creation of APIs that support brain health and enhance the capabilities of the mind, is pleased to announce it has successfully exported naturally derived psilocybin from its facility in Jamaica.

  • GlobeNewswire

    Mycotopia Therapies Announces Plan to Develop Psychedelic Sublingual Tablet to Help Treat Depression

    MIAMI, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Mycotopia Therapies Inc. (OTC Pink: TPIA) (the “Company”), a biopharma company focused on research, technology, and the development of medical psychedelics, announced today it has initiated plans for a psilocybin-based pharmaceutical program by entering into an agreement to form a 50/50 joint venture (the “Joint Venture”) with Agile Pharmaceutical Solutions to develop novel oral dosage forms of psilocybin in the form of a psychedelic sublingual tablet. Th